Skip to content
Menu

Elanco Animal Health Incorporated ELAN

Full chart Compare
Set alert

Price alert · ELAN

All alert types
26.08 USD -0.34 (-1.27%)

As ofNov 17, 2026, 3:25 PM EST

25.74 Day range 26.80
19.40 52-week range 27.98
YTD
+15.22%
1 year
+21.73%
Market cap
13.03B
Revenue (ttm)
5.15B
Profit margin
-2.85%
EPS (ttm)
-0.30
Shares out
499.83M
Forward P/E
20.49
YTD return
+15.22%
1-year return
+21.73%
50-day average
23.38
200-day average
23.86
Volume
1.94M
Avg volume
5.26M
Open
26.56
Previous close
26.41
Day's range
25.74 – 26.80
52-week range
19.40 – 27.98
Beta
1.72
Analysts
Buy
Price target
31.00 (+18.9%)
Earnings date
Feb 23, 2027

5D +0.28 (+1.06%)

26.5027MonTueWedThuFri26.78

Key statistics

Enterprise value
16.94B
PEG ratio
4.04
Price / sales
2.57
Price / book
1.99
Revenue growth
11.30%
Free cash flow
685.12M
Total cash
465.00M
Total debt
4.02B
Return on equity
-2.20%
Short % of float
10.47%

Fundamental scorecard

4 of 25 checks passed on ELAN’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ELAN Revenue — quarterly 1.26B
ELAN Net income — quarterly 18.00M
ELAN EPS — quarterly 0.04

Earnings

ELAN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20260.18———
Nov 6, 2026Sep 30, 20260.20280.27+0.07+33.14%
Aug 5, 2026Jun 30, 20260.26920.34+0.07+26.30%
May 6, 2026Mar 31, 20260.34560.40+0.05+15.74%
Feb 24, 2026Dec 31, 20250.110.13+0.02+18.18%
Nov 5, 2025Sep 30, 20250.130.19+0.06+46.15%

Upgrades / downgrades

ELAN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026JP MorganmainOverweightOverweight
Oct 29, 2026Morgan StanleymainEqual-WeightEqual-Weight
Oct 20, 2026JefferiesdownBuyHold
Oct 16, 2026Goldman Sachsinit—Buy
Aug 6, 2026UBSmainBuyBuy
Aug 6, 2026KeybancmainOverweightOverweight

About Elanco Animal Health Incorporated

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
elanco.com

News

Your note

Sign in to keep a note on ELAN — it syncs with the Stock Master app.

Insider holders

ELAN insider holders
InsiderRelationLatest transactionDateShares held
BETTINGTON TIMOTHY JOfficerSaleOct 14, 2026138,911
CABRAL RAMIRO MARTINOfficerStock Award(Grant)Feb 26, 2026290,366
DE BRABANDER ELLENOfficerStock Award(Grant)Mar 31, 2026280,821
HOOVER R DAVIDDirectorStock Award(Grant)May 20, 2026277,371
KINARD DAVID SOfficerStock Award(Grant)Feb 26, 2026217,697
KURZIUS LAWRENCE ERIKDirectorPurchaseAug 19, 2026188,647

Institution ownership

ELAN institution ownership
Holder% heldSharesValueReported
FMR, LLC13.31%66,540,5141.76BSep 29, 2026
Dodge & Cox Inc.12.29%61,430,9971.62BSep 29, 2026
Blackrock Inc.9.86%49,276,6371.30BSep 29, 2026
Primecap Management Company9.09%45,439,6671.20BSep 29, 2026
T. Rowe Price Investment Management, Inc.5.75%28,750,719760.46MJun 29, 2026
Dimensional Fund Advisors LP5.02%25,069,982663.10MSep 29, 2026

Fund ownership

ELAN fund ownership
Holder% heldSharesValueReported
Dodge & Cox Funds-Dodge & Cox Stock Fund8.62%43,107,5001.14BJun 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%17,796,673470.72MSep 29, 2026
VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund3.55%17,751,139469.52MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%15,872,148419.82MJun 29, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 2.40%11,974,227316.72MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%11,448,318302.81MJun 29, 2026